Corporate Overview February 2026 NASDAQ GS ALXO © ALX Oncology Inc. All rights reserved. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall thereby any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 2 Confidential Forward-looking Statements Certain information set forth i ...

Core Viewpoint - InnoCare Pharma has made significant progress in clinical development, completing patient enrollment in multiple Phase III registrational trials for its cancer and autoimmune disease treatments [1] Group 1: Clinical Development Progress - The company completed patient enrollment in a Phase III trial for the BCL2 inhibitor mesutoclax (ICP-248) combined with BTK inhibitor orelabrutinib for treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients [2] - InnoCare has also accelerated the clinical development of two novel TYK2 inhibitors, completing patient enrollment in the Phase III trial of soficitinib (ICP-332) for moderate to severe atopic dermatitis and in the Phase III trial of ICP-488 for psoriasis [4] - Additionally, patient enrollment has been completed in a Phase II trial of soficitinib for vitiligo, targeting various T-cell related autoimmune disorders [5] Group 2: Drug Mechanisms and Indications - Mesutoclax is a selective oral BCL2 inhibitor that restores normal apoptosis in cancer cells, aiming to provide deeper remission for treatment-naïve CLL/SLL patients [3] - Soficitinib is a potent TYK2 inhibitor being developed for multiple dermatological conditions, including atopic dermatitis, vitiligo, prurigo nodularis, CSU, and psoriasis [5][6] - ICP-488, an oral allosteric TYK2 inhibitor, blocks inflammatory cytokine signaling pathways, addressing autoimmune and inflammatory diseases [6] Group 3: Company Overview - InnoCare is a commercial stage biopharmaceutical company focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases with unmet medical needs [7]

ImmunityBio Inc. (NASDAQ:IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth. This surge follows a strong performance driven by the sales of its lead drug, Anktiva, which has gained traction in the market.The stock has jumped over 50% over the last month, thanks to investor interest after preliminary earnings and several strategic partnerships.Anktiva Sales Surge: 750% Unit IncreaseImmunityBio reported a remarkable year-ove ...

H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The approval in Japan further validates the Alpha DaRT platform and helps de-risk the clinical development in the U.S., the analyst tells investors. Published first on TheFly – the ulti ...

Key Takeaways Iovance's Amtagvi sales jumped 183% in the first nine months of 2025, driving growth.IOVA cut its 2025 revenue guidance and withdrew its EU filing for Amtagvi, hurting shares.Rigel's 2025 sales rose 60% to $232M, led by Tavalisse, with 2026 growth projected.Both Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the successful commercialization of their marketed products.While Iovance is a cancer biotech concentrated on developing immunotherapies ...

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results ...

Core Viewpoint - Exelixis has been gaining recognition in the biotech sector over the past five years, driven by strong financial performance and growth potential, particularly through its cancer drug Cabometyx [1] Financial Performance - Exelixis has shown solid financial results with increasing revenue, earnings, and free cash flow over the past five years, slightly outperforming the S&P 500 during this period [3] Product Success - The success of Exelixis is largely attributed to Cabometyx, which is the top-prescribed cancer drug for renal cell carcinoma and has received multiple label expansions, including combination treatments with established drugs like Bristol Myers Squibb's Opdivo [2] Future Prospects - Exelixis is preparing for potential challenges as Cabometyx may face generic competition by early 2030, but the drug is expected to maintain its market position until then [4] - In March 2025, Cabometyx received approval for treating previously treated advanced neuroendocrine tumors, expanding its market reach [5] Pipeline Development - To mitigate reliance on Cabometyx, Exelixis is developing zanzalintinib, which has completed a phase 3 study for metastatic colorectal cancer, an area with significant unmet medical needs [6] - The company has requested regulatory approval for zanzalintinib in colorectal cancer and plans to explore additional indications, alongside other pipeline candidates that may progress clinically in the coming years [7]

Core Insights - The FDA has approved the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated adult patients with chronic lymphocytic leukemia (CLL), marking a significant advancement in treatment options [1][2] Group 1: FDA Approval and Treatment Significance - The approval is based on data from the Phase 3 AMPLIFY trial, establishing this regimen as the first all-oral, fixed-duration treatment for previously untreated CLL patients [1] - This combination offers patients the potential for time off treatment, enhancing long-term disease management [1][3] - The approval expands treatment choices for patients and healthcare providers, facilitating more targeted treatment decisions in CLL [1][3] Group 2: AMPLIFY Study Details - The AMPLIFY trial evaluated VENCLEXTA plus acalabrutinib against chemoimmunotherapy in previously untreated CLL patients without del(17p) or TP53 mutation [1] - Results indicated that the combination regimen reduced the risk of disease progression or death by 35% compared to chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.0038) [1] - Median progression-free survival (PFS) was not reached for the combination regimen, while it was 47.6 months for chemoimmunotherapy [1] Group 3: Safety Profile - The safety profile of the combination regimen aligns with the known safety profiles of each individual therapy [1] - Common adverse reactions (20%) include neutropenia, headache, diarrhea, musculoskeletal pain, and COVID-19 [1] - Serious adverse reactions (2%) include COVID-19 pneumonia (9%), second primary malignancies (2.7%), and neutropenia (2.1%) [1]

Summary of Sensei Biotherapeutics and Faeth Therapeutics Acquisition Conference Call Company and Industry Overview - **Company**: Sensei Biotherapeutics (NasdaqGM:SNSE) - **Acquisition Target**: Faeth Therapeutics - **Industry**: Biotechnology, specifically focused on cancer treatment Key Points and Arguments 1. **Acquisition Announcement**: Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics, which includes a concurrent financing and changes to the leadership team and board of directors [2][6] 2. **Strategic Rationale**: The acquisition is seen as a means to maximize shareholder value and is expected to create significant value for stockholders [6] 3. **Faeth's Pipeline**: Faeth is a clinical-stage company developing multi-node therapies aimed at blocking cancer growth signals, with its lead asset, PIKTOR, showing promising safety and efficacy data [6][7] 4. **Financing Details**: Sensei entered into a $200 million private placement with support from leading healthcare investors, which will strengthen its financial position [8] 5. **Cash Runway**: The combined cash from the private placement and existing funds is expected to extend Sensei's cash runway through multiple clinical milestones [8] 6. **Leadership Changes**: Anand Parikh, former CEO and co-founder of Faeth, has joined Sensei as COO and a board member [9] 7. **PIKTOR Overview**: PIKTOR is an investigational oral combination therapy targeting the PI3K/AKT/mTOR pathway, designed to improve tolerability and efficacy compared to traditional treatments [10] 8. **Clinical Trial Results**: In a phase 1b trial, PIKTOR achieved a 47% overall response rate in heavily pre-treated patients with various cancers, including an 80% response rate in endometrial cancer patients [11] 9. **Future Trials**: PIKTOR is currently in phase 2 trials for endometrial cancer, with plans for additional studies in breast cancer and other tumor types [12] 10. **Market Potential**: The focus on cancers with mutations in the PI3K/AKT/mTOR pathway presents a significant market opportunity, particularly as treatment standards evolve towards combination strategies [13] 11. **Preclinical Pipeline**: In addition to PIKTOR, Sensei has a preclinical pipeline that includes therapies for rectal cancer and pediatric rare diseases [13] 12. **Acquisition Structure**: The acquisition was structured as a stock-for-stock merger, with Faeth's equity exchanged for Sensei common stock and newly created Series B non-voting convertible preferred stock [15] 13. **Ownership Post-Acquisition**: Post-acquisition, Faeth's equity holders will own approximately 40.8% of Sensei's common stock, while private placement investors will own about 54.3% [17] 14. **Use of Proceeds**: Proceeds from the private placement will primarily be used to advance PIKTOR for key clinical readouts [17] Additional Important Information - **Forward-Looking Statements**: The call included forward-looking statements regarding the expected effects and opportunities related to the acquisition, which involve risks and uncertainties [3][4] - **Investor Communication**: Investors are encouraged to read the proxy statement and other relevant materials filed with the SEC for important information regarding the transactions [5] - **Future Updates**: Sensei plans to provide updates on the progress of its clinical trials and the integration of Faeth in the coming weeks and months [19]

Key Takeaways Rigel Pharmaceuticals expects 2025 sales to rise 60% to $232M, topping prior guidance.Tavalisse drove $158.9M in 2025 sales, up 52%, while Gavreto and Rezlidhia added momentum.RIGL guides 2026 product sales of $255-$265M but faces competition from Sanofi and Eli Lilly drugs.Rigel Pharmaceuticals (RIGL) had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven p ...